Acceleron Pharma (XLRN) Tops Q3 EPS by 10c

Acceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.36), $0.10 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.16 million versus the consensus estimate of $4.38 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• SK Hynix vs. Micron deep dive: who wins the AI memory supercycle?
• Highway Holdings (HIHO) Misses Q4 EPS by 24c
• ConAgra Brands (CAG) Tops Q4 EPS by 1c, Beats on Revenue; Offers FY EPS Guidance